Going Digital - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Going Digital
Software and online monitoring are helping the pharmaceutical industry improve its corrective and preventive action programs. This article contains bonus online material.


Pharmaceutical Technology
Volume 34, Issue 9, pp. 36-40

Each system plays a part


Software from companies such as EtQ (New York) can prompt manufacturers to take corrective actions in response to deviations. (IMAGE IS COURTESY OF ETQ)
Drugmakers often use dedicated software solutions to perform tasks such as maintenance, manufacturing, and analytical testing. Each of these systems can play a part in reducing the deviations that might otherwise trigger a CAPA process. For example, operations-management software uses automated workflows to walk personnel through standard operating procedures step by step, thus ensuring that manufacturing steps are carried out correctly. The software also verifies that equipment has been cleaned or sterilized and that personnel have the training required for a given procedure. By checking this information before performing work and making it available to workers in real time, an operations-management application can help to prevent deviations from happening, thus ensuring the manufacture of acceptable products and saving time that might have been spent on investigations.

A quality-management system (QMS) can confirm the identity, strength, and purity of raw materials and finished products. QMS helps manufacturers maintain accountability by allowing them to assign employees the responsibility for investigating the cause of a given deviation. The software also allows managers to establish a timeline for resolving deviations and to develop a structured escalation process for overdue actions.

Companies have been successful in establishing QMS at a high level, but they often are cited for not implementing it or for not having a uniform process for mitigating deviations, says Michael Sieve, life-sciences solutions engineer at Seapine Software. With an effective CAPA procedure, aided by QMS, organizations can prevent recurring manufacturing failures, save time and resources, and help generate revenue.

Unite and conquer

More and more, pharmaceutical companies are realizing that the information in their various data systems can improve CAPA processes appreciably. During the past few years, manufacturers have begun to flow information from software such as QMS and maintenance systems into their operations-management system. And links between companies' CAPA and operations-management systems are becoming increasingly common, to the point where they are expected for new facilities.

"You're starting to see much more of an integration of information flows between what had been various silos," says Bob Lenich, director of Emerson Process Management's Syncade product platform. If these data systems are linked, an excursion during production automatically triggers a deviation process within a CAPA system. This link helps resolve the deviation faster and allows products to ship sooner as part of the normal release process. Integrating information from laboratory, maintenance, and operations systems is crucial, says Lenich, because it can help the CAPA process find the root cause of production problems early so that they can be avoided.

The case for full conversion

Much of the pharmaceutical industry has automated various steps of the CAPA process such as requirement gathering, event tracking, and testing. But full automation in CAPA is currently not widespread. Manufacturers ultimately need a single system that provides full traceability of requirements through testing, defects, corrective action, and closure so that teams in successive segments of a product's life cycle are informed about previous deviations and understand why particular events were resolved in certain ways. "Being able to automatically inform people about the current status of a product can be invaluable in the long-term life of the product," says Sieve.

Many companies believe that automating CAPA processes is expensive, time-consuming, and does not provide a return on investment. But this belief is mistaken, says Sieve, because some vendors offer an all-encompassing automated CAPA system that is much easier to set up than an enterprise resource planning system, which can require extensive customization. Commercial off-the-shelf software can offer a wealth of configuration options.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here